Talis Biomedical (TLIS)
OTHER OTC:TLIS
US Market
Holding TLIS?
Track your performance easily

Talis Biomedical (TLIS) Income Statement

43 Followers

Talis Biomedical Income Statement

Last quarter (Q2 2024), Talis Biomedical's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Talis Biomedical's net income was $-8.85M. See Talis Biomedical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 149.00K$ 412.00K$ 4.81M-$ 0.00$ 0.00
Cost of Revenue
$ 19.00K$ 41.00K$ -8.39M---
Gross Profit
$ 130.00K$ 371.00K$ -8.39M---
Operating Expense
$ 57.83M$ 67.19M$ 111.56M$ 200.01M$ 91.18M$ 26.70M
Operating Income
$ -57.64M$ -68.95M$ -119.95M$ -200.01M$ -91.18M$ -26.70M
Net Non Operating Interest Income Expense
----$ 54.00K$ 42.00K
Other Income Expense
$ -5.25M$ 4.81M$ -6.94M$ -7.97M$ 54.00K$ -817.00K
Pretax Income
$ -52.60M$ -62.01M$ -113.01M$ -192.04M$ -91.13M$ -27.47M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -52.60M$ -62.01M$ -113.01M$ -192.04M$ -91.13M$ 26.38M
Basic EPS
$ -28.90$ -34.12$ -4.24$ -8.48$ -4.63$ -13.42
Diluted EPS
$ -28.90$ -34.12$ -4.24$ -8.48$ -4.63$ -13.42
Basic Average Shares
$ 7.28M$ 1.82M$ 26.63M$ 22.66M$ 19.68M$ 2.26M
Diluted Average Shares
$ 7.28M$ 1.82M$ 26.63M$ 22.66M$ 19.68M$ 2.26M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 57.85M$ 67.23M$ 103.17M$ 200.01M$ 91.18M$ 26.70M
Net Income From Continuing And Discontinued Operation
$ -52.60M$ -62.01M$ -113.01M$ -192.04M$ -91.13M$ -27.47M
Normalized Income
$ -37.16M---$ -91.13M$ -27.47M
Interest Expense
------
EBIT
$ -53.89M$ -62.01M$ -113.01M$ -192.04M$ -91.18M$ -26.70M
EBITDA
$ -53.16M$ -61.24M$ -104.18M$ -190.46M$ -90.42M$ -25.97M
Currency in USD

Talis Biomedical Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis